Keyora Skin Systems Nutrition - Collagen Tripeptides EP-5: The Fibroblast-to-Matrix Evidence Continuum: From Gly-Pro-Hyp and Pro-Hyp Recognition Biology to Cellular Signaling and Extracellular Matrix Responses

Dermal extracellular matrix (ECM) maintenance depends on fibroblast identity, cellular activity, intracellular signaling, and coordinated synthesis and organization of collagen, elastin, fibronectin, and hyaluronic acid. Although oral collagen-derived peptides can appear in human circulation, systemic exposure does not independently establish receptor binding, fibroblast activation, or clinical skin improvement. Keyora Skin Systems Nutrition - Collagen Tripeptides EP-5 develops the Keyora Fibroblast-to-Matrix Evidence Continuum and Keyora Fibroblast Evidence Ladder to connect molecularly defined peptides with experimentally verified cellular responses while preserving these evidence boundaries. Chapter 1 examines dermal fibroblast heterogeneity, including papillary, reticular, and transcriptionally distinct populations. Aging, ultraviolet exposure, oxidative stress, and collagen fragmentation influence fibroblast morphology, procollagen synthesis, and matrix regulation. The framework distinguishes collagen-related transcription, protein synthesis, precursor secretion, extracellular processing, and organized fibril formation as separate biological stages. Chapter 2 evaluates peptide-specific fibroblast experiments. Early studies by Postlethwaite and colleagues demonstrated chemotactic responses to collagen-derived fragments. Shigemura et al. (2009) identified Pro-Hyp-associated fibroblast growth under matrix-dependent culture conditions. Ohara et al. (2010) reported that 200 µM Pro-Hyp increased cultured human dermal fibroblast proliferation approximately 1.5-fold, HAS2 expression 2.3-fold, and hyaluronic acid synthesis 3.8-fold. Chae et al. (2023) separately associated Gly-Pro-Hyp (GPH) with favorable collagen-related, elastin, and fibronectin transcriptional responses under oxidative challenge. Chapter 3 distinguishes established extracellular receptor biology from unverified free-peptide recognition. Collagen-binding integrins recognize structural collagen motifs, DDR1/DDR2 respond to collagen-dependent ligands, and CD44 participates in hyaluronan recognition. These mechanisms do not establish direct binding of soluble GPH or Pro-Hyp to those receptors. Ligand-specific binding, competition, receptor perturbation, and functional rescue are necessary for stronger target attribution. Chapter 4 examines intracellular mechanisms and ECM outcomes. Pro-Hyp-associated STAT3 phosphorylation, HAS2 regulation, and hyaluronan synthesis possess experimental support, whereas GPH-associated ECM transcriptional responses represent a separate molecular pathway. UV-related MMP-1 and type I procollagen measurements provide additional cellular evidence. MAPK, TGF-beta/Smad, and other established fibroblast pathways cannot automatically be assigned to orally administered GPH. Chapter 5 integrates these observations through the Keyora Fibroblast Evidence Ladder. Keyora's tilapia-scale-derived ingredient supplies 1,500 mg hydrolysed collagen tripeptide powder per two-tablet serving, with a declared 30% tripeptide fraction and reported 459 Da mean molecular weight. These characteristics do not establish an independently quantified GPH dose, human fibroblast exposure, or finished-formula efficacy. Preparation-specific clinical studies report selected skin improvements but cannot validate the exact Keyora formulation. EP-5 concludes that molecular identity, systemic exposure, fibroblast phenotype, receptor evidence, intracellular signaling, ECM production, and human skin outcomes require distinct verification. The resulting framework supports preparation-matched mechanistic research without treating cellular responses as demonstrated clinical skin regeneration.